Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ (14,859,000)	$ 4,134,000	$ (23,982,000)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	6,704,000	6,480,000	6,083,000
Amortization of acquisition related intangible assets	7,783,000	7,837,000	7,381,000
Amortization of acquisition related inventory step-up	0	6,465,000	11,082,000
Non-cash operating lease cost	1,850,000	1,708,000	1,531
Goodwill impairment charge	0	0	42,520,000
Change in fair value of contingent consideration	0	(21,095,000)	(28,666,000)
Loss on disposal of fixed assets	0	993,000	265,000
Loss on impairment of intangible asset	0	600,000	2,439,000
Stock-based compensation expense	14,315,000	11,085,000	5,386,000
Deferred income taxes	(5,270,000)	(1,766,000)	(3,543,000)
Provision for doubtful accounts	378,000	64,000	549,000
Provision for inventory	5,329,000	6,628,000	5,490,000
Other	0	(18,000)	(12,000)
Changes in operating assets and liabilities:
Accounts receivable	(5,630,000)	(6,216)	5,855,000
Inventories	(6,873,000)	(6,619,000)	(14,177,000)
Prepaid expenses, other current and long-term assets	(792,000)	1,424,000	(1,783,000)
Accounts payable	1,965,000	(1,100,000)	822,000
Operating lease liabilities	(1,485,000)	(1,626,000)	(1,439,000)
Accrued expenses, other current and long-term liabilities	(443,000)	3,510,000	(142,000)
Income taxes	1,437,000	(1,311,000)	(2,072,000)
Payments of contingent consideration	0	(2,780,000)	(522,000)
Net cash provided by operating activities	4,409,000	8,397,000	13,065,000
Cash flows from investing activities:
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired	0	(476,000)	(94,601,000)
Proceeds from maturities of investments	0	2,501,000	45,000,000
Purchases of investments	0	0	(20,035.000)
Purchases of property and equipment	(7,486,000)	(5,143,000)	(1,628,000)
Net cash (used in) provided by investing activities	(7,486,000)	(3,118,000)	(71,264,000)
Cash flows from financing activities:
Payments made on finance leases	(284,000)	(201,000)	(208,000)
Proceeds from long-term debt	0	0	50,000,000
Repayments of long-term debt	0	0	(50,350,000)
Proceeds from employee stock purchase program	665,000	0	0
Cash paid for tax withheld on vested restricted stock awards	(934,000)	(486,000)	(262,000)
Proceeds from exercises of equity awards	16,000	1,128,000	1,524,000
Payments of contingent consideration	(4,315,000)	(7,220,000)	(4,478,000)
Net cash used by financing activities	(4,852,000)	(6,779,000)	(3,774,000)
Exchange rate impact on cash	(130,000)	69,000	327,000
Decrease in cash and cash equivalents	(8,059,000)	(1,431,000)	(61,646,000)
Cash and cash equivalents at beginning of period	94,386,000	95,817,000	157,463,000
Cash and cash equivalents at end of period	86,327,000	94,386,000	95,817,000
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds	106,000	1,233,000	993,000
Right-of-use assets obtained in exchange for operating lease liabilities	2,471,000	2,392,000
Purchases of property and equipment included in accounts payable and accrued expenses	108,000	15,000	17,000
Consideration for acquisitions included in accounts payable and accrued expenses	0	0	476,000
Contingent consideration fair value on acquisition date	0	0	69,076,000
Accounting Standards Update 2016-02 [Member]
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities	$ 11,703,000	$ 220,000	$ 0